Acadia Pharmaceuticals Inc. (ACAD) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $20.64 (-0.55%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 23, 2026 | Rudy Li | Wolfe Research | $33.00 | +59.8% |
| Jan 6, 2026 | Ashwani Verma | UBS | $40.00 | +93.8% |
| Dec 11, 2025 | Paul Matteis | Stifel Nicolaus | $25.00 | +21.1% |
| Dec 4, 2025 | Ashwani Verma | UBS | $35.00 | +69.5% |
| Aug 8, 2025 | Ashwani Verma | UBS | $36.00 | +74.4% |
| Jun 26, 2025 | Matthew Hershenhorn | Oppenheimer | $22.00 | +6.6% |
| May 20, 2025 | Sean Laaman | Morgan Stanley | $24.00 | +16.3% |
| May 19, 2025 | Andrew Fein | H.C. Wainwright | $32.00 | +55.0% |
| May 19, 2025 | Ami Fadia | Needham | $30.00 | +45.3% |
| Jan 3, 2025 | Yatin Suneja | Guggenheim | $20.00 | -3.1% |
| Aug 7, 2024 | Jeffrey Hung | Morgan Stanley | $20.00 | -3.1% |
| Jun 26, 2024 | Keith Tapper | BMO Capital | $31.00 | +50.2% |
| May 9, 2024 | Andrew Fein | H.C. Wainwright | $27.00 | +30.8% |
| May 9, 2024 | Joel Beatty | Robert W. Baird | $28.00 | +35.6% |
| May 9, 2024 | Uy Ear | Mizuho Securities | $21.00 | +1.7% |
| Apr 30, 2024 | Ashwani Verma | UBS | $27.00 | +30.8% |
| Mar 12, 2024 | Ashwani Verma | UBS | $33.00 | +59.8% |
| Mar 12, 2024 | Jay Olson | Oppenheimer | $19.00 | -8.0% |
| Mar 12, 2024 | Ami Fadia | Needham | $32.00 | +55.0% |
| Mar 12, 2024 | Sumant Kulkami | Canaccord Genuity | $33.00 | +59.8% |
Top Analysts Covering ACAD
ACAD vs Sector & Market
| Metric | ACAD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.25 | 2.41 |
| Analyst Count | 26 | 8 | 19 |
| Target Upside | +45.1% | +153002.0% | +21.5% |
| P/E Ratio | 9.38 | 3.46 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $330M | $340M | $345M | 5 |
| 2027-12-31 | $1.31B | $1.39B | $1.46B | 14 |
| 2028-12-31 | $1.57B | $1.57B | $1.57B | 16 |
| 2029-12-31 | $1.59B | $1.67B | $1.72B | 15 |
| 2030-12-31 | $1.75B | $1.84B | $1.90B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.15 | $0.16 | $0.16 | 3 |
| 2027-12-31 | $0.01 | $0.84 | $1.63 | 10 |
| 2028-12-31 | $0.62 | $1.57 | $2.85 | 15 |
| 2029-12-31 | $1.78 | $1.90 | $1.98 | 10 |
| 2030-12-31 | $2.44 | $2.59 | $2.70 | 6 |
Frequently Asked Questions
What is the analyst consensus for ACAD?
The consensus among 26 analysts covering Acadia Pharmaceuticals Inc. (ACAD) is Buy with an average price target of $32.32.
What is the highest price target for ACAD?
The highest price target for ACAD is $62.00, set by Pito Chickering at Deutsche Bank on 2021-04-19.
What is the lowest price target for ACAD?
The lowest price target for ACAD is $19.00, set by Jay Olson at Oppenheimer on 2024-03-12.
How many analysts cover ACAD?
26 analysts have issued ratings for Acadia Pharmaceuticals Inc. in the past 12 months.
Is ACAD a buy or sell right now?
Based on 26 analyst ratings, ACAD has a consensus rating of Buy (2.12/5) with a +45.1% upside to the consensus target of $32.32.
What are the earnings estimates for ACAD?
Analysts estimate ACAD will report EPS of $0.16 for the period ending 2026-12-31, with revenue estimated at $340M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.